Repligen (RGEN) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Repligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017
February 22, 2017 7:30 AM ESTFourth quarter 2016 revenue of $25.6 million reflects 19% growthFull year 2016 revenue of $104.5 reflects 25% growthFull year 2016 GAAP and adjusted operating income grew 16% and 20% respectively
WALTHAM, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the fourth quarter ended December 31, 2016. Detailed in this press release are the Company's performance highlights for the quarter and full year periods, followed by initial financial guidance for the year 2017 and access information for today's webcast and conference call.
... More